Palatin Technologies, Inc. (PTN)
+0.070 (4.07%)
Apr 23, 2024, 12:15 PM EDT - Market open

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.

In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.

Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials.

The company was founded in 1986 and is based in Cranbury, New Jersey.

Palatin Technologies, Inc.
Palatin Technologies logo
Country United States
Founded 1986
IPO Date Oct 28, 1993
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Dr. Carl Spana Ph.D.

Contact Details

4b Cedar Brook Drive
Cranbury, New Jersey 08512
United States
Phone 609-495-2200

Stock Details

Ticker Symbol PTN
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000911216
CUSIP Number 696077403
ISIN Number US6960775020
Employer ID 95-4078884
SIC Code 2834

Key Executives

Name Position
Dr. Carl Spana Ph.D. Co-Founder, President, Chief Executive Officer and Director
Stephen T. Wills CPA, MST Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Burns McClellan Vice President of Investor Relations
Stephen A. Slusher Esq. Chief Legal Officer
Dr. Michael B. Raizman M.D. Chief Medical Officer
James E. Hattersley Senior Vice President of Business Development
John Dodd Ph.D. Senior Vice President of Preclinical Development
Robert Jordan Senior Vice President of Program Operations

Latest SEC Filings

Date Type Title
Mar 28, 2024 EFFECT Notice of Effectiveness
Mar 28, 2024 424B3 Prospectus
Mar 14, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Mar 4, 2024 144 Filing
Feb 15, 2024 8-K Current Report
Feb 14, 2024 10-Q Quarterly Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 8-K Current Report
Feb 1, 2024 424B5 Filing
Dec 20, 2023 8-K Current Report